Lipella Pharmaceuticals Inc. (LIPO) Key Metrics
LIPO valuation today
Trailing 12 months · as of October 21, 2026- Market cap
- $2,310
- Enterprise value
- −$1.6M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 0.0
- Price / book
- 0.0
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 1.89
LIPO key metrics, 2019–2024
Fiscal year ended December 31, 2024 · U.S. dollarsLIPO returns How much profit the business earns on the capital it uses.
LIPO financial health Debt, liquidity and how easily interest is covered.
LIPO efficiency & capital use Working capital cycle and where the cash goes.
LIPO returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
LIPO debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
LIPO key metrics
2019–2024| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|
| Per share | ||||||
| Revenue per share | $0.51 | — | — | — | — | — |
| Earnings per share | −$4.79 | — | — | — | — | — |
| Operating cash flow per share | −$3.77 | — | — | — | — | — |
| Free cash flow per share | −$3.77 | — | — | — | — | — |
| Cash per share | $2.08 | — | — | — | — | — |
| Book value per share | $1.83 | — | — | — | — | — |
| Tangible book value per share | $1.83 | — | — | — | — | — |
| Capex per share | $0.00 | — | — | — | — | — |
| Debt per share | $0.05 | — | — | — | — | — |
| Shares outstanding | 1.0M | — | — | — | — | — |
| Returns & profitability | ||||||
| Return on equity (ROE) | −198.1% | −118.1% | −85.2% | −197.7% | −35.7% | — |
| Return on invested capital (ROIC) | — | — | — | — | −44.7% | — |
| Return on assets (ROA) | −160.5% | −97.0% | −65.2% | −125.7% | −11.5% | −52.0% |
| Return on tangible assets | −187.6% | −129.1% | −43.7% | −92.7% | −6.5% | −52.0% |
| Free cash flow margin | −736.6% | −703.8% | −994.4% | −381.4% | −3.0% | −5.6% |
| Financial health | ||||||
| Total debt | $47,605 | $136,594 | $429,520 | $282,961 | $388,912 | $100,000 |
| Cash & short-term investments | $2.2M | $3.3M | $5.1M | $1.7M | $606,736 | $26,005 |
| Net debt | −$2.1M | −$3.2M | −$4.7M | −$1.4M | −$217,824 | $73,995 |
| Debt / equity | 0.02 | 0.04 | 0.09 | 0.20 | 0.84 | — |
| Debt / assets | 0.02 | 0.04 | 0.07 | 0.14 | 0.41 | 0.84 |
| Net debt / EBITDA | — | — | — | — | — | 221.54 |
| Current ratio | 3.47 | 8.90 | 4.92 | 5.31 | 3.37 | 0.72 |
| Quick ratio | 3.47 | 8.90 | 5.02 | 5.31 | 3.37 | 0.72 |
| Interest coverage | — | -437.5 | -269.4 | -280.3 | -7.1 | -6.4 |
| Working capital | $1.9M | $3.0M | $4.6M | $1.5M | $491,658 | −$46,755 |
| Invested capital | −$217,805 | −$12,696 | −$16,627 | −$7,861 | $245,493 | −$44,347 |
| Tangible asset value | $1.9M | $3.1M | $4.7M | $1.4M | $463,317 | −$118,342 |
| Net current asset value | $1.9M | $3.0M | $4.5M | $1.2M | $207,723 | −$118,342 |
| Graham net-net per share | $1.43 | — | — | — | — | — |
| Capital allocation | ||||||
| Capex / revenue | 0.0% | 3.2% | 0.0% | 0.0% | 0.0% | 0.0% |
| Capex / depreciation | 0.00 | 8.57 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-based compensation / revenue | 139.7% | 301.4% | 405.8% | 281.0% | 6.0% | — |
| R&D / revenue | 673.7% | 675.9% | 1,383.4% | 561.7% | 101.5% | 98.3% |
| SG&A / revenue | 373.6% | 479.7% | 122.8% | 277.0% | 4.4% | 9.4% |
| Efficiency | ||||||
| Days sales outstanding | 39.8 | 59.2 | 225.3 | — | 29.0 | 44.1 |
| Days of inventory on hand | — | — | -16.3 | — | — | — |
| Days payables outstanding | 26.6 | 31.4 | 30.9 | 8.9 | 13.8 | 26.4 |
| Cash conversion cycle (days) | 13.2 | 27.9 | 178.1 | — | 15.2 | 17.7 |
| Receivables turnover | 9.17 | 6.16 | 1.62 | — | 12.58 | 8.28 |
| Payables turnover | 13.73 | 11.63 | 11.82 | 40.78 | 26.42 | 13.84 |
| Asset turnover | 0.17 | 0.09 | 0.05 | 0.17 | 1.79 | 5.84 |
| Average receivables | $58,500 | $72,970 | $113,655 | — | $76,463 | $83,891 |
| Average payables | $263,104 | $261,186 | $215,628 | $35,720 | $36,940 | $49,341 |
| Average inventory | — | — | −$113,655 | — | — | — |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from LIPO's annual financial statements (latest annual report filed March 28, 2025) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
LIPO valuation and financial ratios
Lipella Pharmaceuticals earned a return on equity of −198.1% in fiscal 2024. It ended the year with $0.0 million of debt and $2.2 million in cash and short-term investments, a net cash position of $2.1 million.
See the LIPO income statement, the LIPO chart for price history, or the LIPO stock overview for the latest quote and news.
LIPO key metrics FAQ
What is Lipella Pharmaceuticals's return on equity?
Lipella Pharmaceuticals's return on equity (ROE) was −198.1% in fiscal 2024: net income of -$5.0 million on average shareholders' equity of $2.5 million.
How much debt does Lipella Pharmaceuticals have?
Lipella Pharmaceuticals had total debt of $0.0 million at the end of fiscal 2024, a debt-to-equity ratio of 0.02 and more cash than debt.
What is Lipella Pharmaceuticals's current ratio?
Lipella Pharmaceuticals's current ratio was 3.47 at the end of fiscal 2024: current assets were 3.47 times current liabilities.